The trial design was developed based on our prior mouse modeling demonstrating that DC covaccination with adoptive transfer of antitumor T cells provides superior tumor control.24 In this setting, the treatment of melanoma tumor bearing mice with the adoptive transfer of transgenic T cells recognizing the gp100 antigen with concomitant intravenous infusion of gp100-pulsed bone-marrow derived DCs resulted in improved tumor control and T-cell persistence as compared with the mice treated with T cells only. This evidence concerns the gene PMEL and neoplasm.